Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) EBT Margin (2016 - 2025)

Myriad Genetics (MYGN) has disclosed EBT Margin for 17 consecutive years, with 4.24% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin rose 1437.0% to 4.24% in Q4 2025 year-over-year; TTM through Dec 2025 was 47.92%, a 3318.0% decrease, with the full-year FY2025 number at 47.92%, down 3318.0% from a year prior.
  • EBT Margin was 4.24% for Q4 2025 at Myriad Genetics, up from 12.74% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 23.79% in Q3 2021 to a low of 155.14% in Q2 2025.
  • A 5-year average of 25.21% and a median of 17.01% in 2023 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: surged 20143bps in 2021, then plummeted -13755bps in 2025.
  • Myriad Genetics' EBT Margin stood at 27.05% in 2021, then fell by -8bps to 29.3% in 2022, then skyrocketed by 44bps to 16.43% in 2023, then fell by -13bps to 18.61% in 2024, then surged by 77bps to 4.24% in 2025.
  • Per Business Quant, the three most recent readings for MYGN's EBT Margin are 4.24% (Q4 2025), 12.74% (Q3 2025), and 155.14% (Q2 2025).